Patents by Inventor Hirofumi Sakumoto

Hirofumi Sakumoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CLDN6 antibody
    Patent number: 9274119
    Abstract: The present invention relates to an antibody binding to Claudin6 (CLDN6) expressed on a cell membrane. The antibody of the present invention recognizes human CLDN6 present in a native form on cell membrane surface and exhibits cytotoxicity through ADCC and/or CDC activities against cancer cell lines highly expressing human CLDN6. Moreover, the antibody of the present invention has cell growth inhibitory effect through conjugation with toxin on cancer cell lines highly expressing human CLDN6. The human CLDN6 is overexpressed in tumor tissues (lung adenocarcinoma, gastric cancer, and ovarian cancer), although its expression is not observed in normal tissues. Thus, the anti-CLDN6 antibody is expected to highly accumulate in tumors highly expressing human CLDN6 and can serve as a very effective antitumor agent.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: March 1, 2016
    Assignees: THE UNIVERSITY OF TOKYO, CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Hiroyuki Aburatani, Shuichi Tsutsumi, Kunihiro Nishimura, Hirofumi Sakumoto, Shigeto Kawai
  • ANTI-CLDN6 ANTIBODY
    Publication number: 20110059469
    Abstract: The present invention relates to an antibody binding to Claudin6 (CLDN6) expressed on a cell membrane. The antibody of the present invention recognizes human CLDN6 present in a native form on cell membrane surface and exhibits cytotoxicity through ADCC and/or CDC activities against cancer cell lines highly expressing human CLDN6. Moreover, the antibody of the present invention has cell growth inhibitory effect through conjugation with toxin on cancer cell lines highly expressing human CLDN6. The human CLDN6 is overexpressed in tumor tissues (lung adenocarcinoma, gastric cancer, and ovarian cancer), although its expression is not observed in normal tissues. Thus, the anti-CLDN6 antibody is expected to highly accumulate in tumors highly expressing human CLDN6 and can serve as a very effective antitumor agent.
    Type: Application
    Filed: January 9, 2009
    Publication date: March 10, 2011
    Inventors: Hiroyuki Aburatani, Shuichi Tsutsumi, Kunihiro Nishimura, Hirofumi Sakumoto, Shigeto Kawai